Clinical Trial Update: Study Evaluating PRA-027 Multiple Ascending Doses In Cycling And Postmenopausal Women [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating PRA-027 at multiple ascending doses in cycling and postmenopausal women with uterine fibroids has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Leiomyomata

Drugs mentioned

• PRA-027

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Uterine Leiomyomata (Fibroids) | Phase 1 | Status: COMPLETED